Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Editorial

Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed

Author(s): George N. Konstantinou* and Maria Petrodimopoulou

Volume 17, Issue 2, 2023

Published on: 18 April, 2023

Page: [85 - 87] Pages: 3

DOI: 10.2174/2772270817666230320153734

Price: $65

conference banner
« Previous Next »
[1]
Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol 2017; 140(4): 950-8.
[http://dx.doi.org/10.1016/j.jaci.2017.03.050] [PMID: 28602936]
[2]
Alvaro-Lozano M, Akdis CA, Akdis M, et al. Allergen immunotherapy in children user’s guide. Pediatr Allergy Immunol 2020; 31(S25) (Suppl. 25): 1-101.
[http://dx.doi.org/10.1111/pai.13189] [PMID: 32436290]
[3]
Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341(7): 468-75.
[http://dx.doi.org/10.1056/NEJM199908123410702] [PMID: 10441602]
[4]
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75(5): 1023-42.
[http://dx.doi.org/10.1111/all.14221] [PMID: 32034960]
[5]
Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy 2021; 76(8): 2337-53.
[http://dx.doi.org/10.1111/all.14809] [PMID: 33683704]
[6]
Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: A systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy 2020; 34(2): 196-208.
[http://dx.doi.org/10.1177/1945892419884774] [PMID: 31672020]
[7]
Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62(8): 943-8.
[http://dx.doi.org/10.1111/j.1398-9995.2007.01451.x] [PMID: 17620073]
[8]
Bukantz SC, Bagg AS, Lockey RF. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008; 21: 455-68.
[PMID: 18828523]
[9]
Pitsios C, Tsoumani M, Bilò MB, et al. Contraindications to immunotherapy: A global approach. Clin Transl Allergy 2019; 9(1): 45.
[http://dx.doi.org/10.1186/s13601-019-0285-4] [PMID: 31528333]
[10]
Tanno LK, Martin B. Biologic agents for the treatment of anaphylaxis. Immunol Allergy Clin North Am 2020; 40(4): 625-33.
[http://dx.doi.org/10.1016/j.iac.2020.06.006] [PMID: 33012324]
[11]
Casale T, Busse W, Kline J, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1): 134-40.
[http://dx.doi.org/10.1016/j.jaci.2005.09.036] [PMID: 16387596]
[12]
Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125(2): 383-9.
[http://dx.doi.org/10.1016/j.jaci.2009.11.022] [PMID: 20159249]
[13]
Lambert N, Guiddir T, Amat F, Just J. Pre-treatment by omalizumab allows allergen immunotherapy in children and young adults with severe allergic asthma. Pediatr Allergy Immunol 2014; 25(8): 829-32.
[http://dx.doi.org/10.1111/pai.12306] [PMID: 25387446]
[14]
Stelmach I, Majak P. Jerzyńska J, Bojo M, Cichalewski Ł, Smejda K. Letter to the Editor Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: A case series from Poland. Arch Med Sci 2015; 4(4): 901-4.
[http://dx.doi.org/10.5114/aoms.2015.48546] [PMID: 26322106]
[15]
Corren J, Saini SS, Gagnon R, et al. Short-term subcutaneous allergy immunotherapy and dupilumab are well tolerated in allergic rhinitis: A randomized trial. J Asthma Allergy 2021; 14: 1045-63.
[http://dx.doi.org/10.2147/JAA.S318892] [PMID: 34429614]
[16]
Aguilar-Pimentel A, Graessel A, Alessandrini F, et al. Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma. PLoS One 2017; 12(6): e0178563.
[http://dx.doi.org/10.1371/journal.pone.0178563] [PMID: 28570653]
[17]
Russkamp D, Aguilar-Pimentel A, Alessandrini F, et al. IL ‐4 receptor α blockade prevents sensitization and alters acute and long‐lasting effects of allergen‐specific immunotherapy of murine allergic asthma. Allergy 2019; 74(8): all.13759.
[http://dx.doi.org/10.1111/all.13759] [PMID: 30829405]
[18]
Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109(2): 274-80.
[http://dx.doi.org/10.1067/mai.2002.121949] [PMID: 11842297]
[19]
Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39(2): 271-9.
[http://dx.doi.org/10.1111/j.1365-2222.2008.03121.x] [PMID: 19016798]
[20]
Kopp MV, Hamelmann E, Bendiks M, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol 2013; 24(5): 427-33.
[http://dx.doi.org/10.1111/pai.12098] [PMID: 23799935]
[21]
Gülsen A, Wallis S, Jappe U. Combination of immunotherapies for severe allergic asthma. J Asthma 2021; 58(1): 75-8.
[http://dx.doi.org/10.1080/02770903.2019.1658204] [PMID: 31486698]
[22]
Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120(3): 688-95.
[http://dx.doi.org/10.1016/j.jaci.2007.05.034] [PMID: 17631952]
[23]
Konstantinou GN, Kaitalidou E, Skoulikaris N. Sublingual immunotherapy and omalizumab cured allergic chronic rhinosinusitis and asthma: coincidence or synergistic effect? Ann Allergy Asthma Immunol 2019; 123(5): 440-3.
[http://dx.doi.org/10.1016/j.anai.2019.08.010] [PMID: 31445089]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy